How long can Ustekinumab treat psoriasis without recurrence?

Ustekinumab is a monoclonal antibody targeting IL-12 and IL-23 and is widely used to treat moderate to severe plaque psoriasis. This drug effectively inhibits the occurrence and spread of psoriasis lesions by regulating the expression of inflammatory factors in the immune system. Most patients can achieve significant and rapid improvement in skin lesions after receiving ustekinumab treatment and enter the clinical remission stage, providing the possibility of long-term disease control.
In terms of maintaining efficacy, ustekinumab showed good durability. Clinical studies have shown that after continuous treatment, most patients' skin lesions can improve for 6 months to more than 1 year, and some can even last longer without recurrence. Under standard treatment regimens (such as injections every 12 weeks after the initial dose), patients can usually achieve stable control of symptoms and reduce the frequency and intensity of recurring skin lesions. Some studies have also found that some patients can remain in remission for a longer period of time even after stopping the drug.

However, the duration of ustekinumab varies among individuals. Some patients may experience recurrence of skin lesions after several months, especially those with other immune system diseases, emotional stress, or irregular lifestyles. Such people may need to adjust the treatment plan according to their specific conditions, such as shortening the dosing interval or combining it with other drugs to maintain the effect.
Overall, ustekinumab can not only quickly relieve symptoms in the treatment of psoriasis, but also has a long-term maintenance effect. In order to prolong the remission period, patients should take regular injections as prescribed by their doctor, follow a healthy lifestyle, and have regular follow-up visits to monitor their condition. This can maximize the time that skin lesions do not recur and improve quality of life and treatment satisfaction.
Reference: https://www.drugs.com/